Quantum BioPharma Submits MS Drug Candidate to UK ILAP Program

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced the submission of its patented multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK's Innovative Licensing and Access Pathway (ILAP) Passport program by its subsidiary, Huge Biopharma Australia Pty Ltd. The ILAP program is designed to fast-track the development and approval of innovative treatments by bringing together developers, regulators, and the NHS. Lucid-MS represents a first-in-class therapy aimed at addressing demyelination, the core issue in multiple sclerosis. This move aligns with Quantum BioPharma's global strategy to expedite clinical progress and enhance patient access through strategic regulatory pathways.

The submission of Lucid-MS to the ILAP program underscores the potential of this therapy to make a significant impact on the treatment of multiple sclerosis, a condition that affects millions worldwide. By leveraging the ILAP program, Quantum BioPharma is positioning Lucid-MS for accelerated review and potential early access, highlighting the company's commitment to addressing unmet medical needs in neurodegenerative disorders.